 Austin Gillen
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hibernation | 3 | 2026 | 82 | 1.720 |
Why?
| | Single-Cell Analysis | 8 | 2025 | 361 | 1.560 |
Why?
| | Polyadenylation | 4 | 2022 | 39 | 1.500 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 8 | 2025 | 373 | 1.470 |
Why?
| | Sciuridae | 3 | 2026 | 152 | 1.060 |
Why?
| | Torpor | 3 | 2026 | 19 | 1.030 |
Why?
| | Programming Languages | 1 | 2025 | 24 | 0.890 |
Why?
| | Transcriptome | 6 | 2025 | 1042 | 0.830 |
Why?
| | Information Storage and Retrieval | 1 | 2025 | 123 | 0.820 |
Why?
| | Reperfusion Injury | 1 | 2026 | 292 | 0.780 |
Why?
| | Leukemia, Myeloid, Acute | 7 | 2025 | 688 | 0.780 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2020 | 81 | 0.760 |
Why?
| | Software | 3 | 2025 | 680 | 0.740 |
Why?
| | Respiratory Mucosa | 2 | 2025 | 322 | 0.630 |
Why?
| | Sequence Analysis, RNA | 8 | 2025 | 442 | 0.610 |
Why?
| | Gene Expression Regulation | 6 | 2023 | 2601 | 0.600 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 7 | 2025 | 280 | 0.590 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 534 | 0.550 |
Why?
| | Kidney | 1 | 2026 | 1497 | 0.550 |
Why?
| | Chromosomes, Artificial, Bacterial | 2 | 2019 | 21 | 0.540 |
Why?
| | Ependymoma | 1 | 2020 | 176 | 0.540 |
Why?
| | Sulfonamides | 7 | 2025 | 583 | 0.520 |
Why?
| | Transgenes | 2 | 2019 | 190 | 0.510 |
Why?
| | Neoplastic Stem Cells | 5 | 2025 | 409 | 0.500 |
Why?
| | Breast Neoplasms | 7 | 2020 | 2393 | 0.500 |
Why?
| | Immunoprecipitation | 2 | 2016 | 149 | 0.490 |
Why?
| | Gene Regulatory Networks | 2 | 2018 | 318 | 0.470 |
Why?
| | Carcinogenesis | 1 | 2017 | 228 | 0.450 |
Why?
| | 3' Untranslated Regions | 5 | 2022 | 149 | 0.450 |
Why?
| | Artifacts | 1 | 2016 | 143 | 0.450 |
Why?
| | Mitochondrial Proteins | 1 | 2017 | 263 | 0.440 |
Why?
| | RNA-Binding Proteins | 3 | 2023 | 447 | 0.430 |
Why?
| | Cystic Fibrosis | 3 | 2025 | 1163 | 0.420 |
Why?
| | Binding Sites | 2 | 2016 | 1311 | 0.390 |
Why?
| | MicroRNAs | 4 | 2016 | 686 | 0.380 |
Why?
| | Hematopoietic Stem Cells | 3 | 2026 | 435 | 0.370 |
Why?
| | Receptors, Estrogen | 5 | 2020 | 404 | 0.370 |
Why?
| | Mitochondria | 3 | 2025 | 994 | 0.350 |
Why?
| | Gene Transfer Techniques | 1 | 2013 | 187 | 0.350 |
Why?
| | RNA | 2 | 2023 | 912 | 0.330 |
Why?
| | Regulatory Sequences, Nucleic Acid | 3 | 2019 | 92 | 0.330 |
Why?
| | Repressor Proteins | 2 | 2011 | 429 | 0.330 |
Why?
| | Homeodomain Proteins | 5 | 2023 | 523 | 0.300 |
Why?
| | Cell Differentiation | 4 | 2021 | 2050 | 0.290 |
Why?
| | Animals | 23 | 2026 | 38106 | 0.290 |
Why?
| | Mammals | 2 | 2023 | 286 | 0.290 |
Why?
| | Interferon-gamma | 1 | 2011 | 784 | 0.270 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2025 | 1450 | 0.260 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2020 | 265 | 0.250 |
Why?
| | Reperfusion | 1 | 2026 | 54 | 0.240 |
Why?
| | Transcription, Genetic | 2 | 2012 | 1454 | 0.240 |
Why?
| | Humans | 42 | 2026 | 145785 | 0.230 |
Why?
| | Niacinamide | 1 | 2026 | 104 | 0.230 |
Why?
| | Arousal | 1 | 2026 | 157 | 0.230 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2025 | 15 | 0.220 |
Why?
| | Mice | 17 | 2025 | 18358 | 0.220 |
Why?
| | Signal Transduction | 7 | 2025 | 5226 | 0.220 |
Why?
| | Gene Expression | 2 | 2023 | 1478 | 0.220 |
Why?
| | Osteolysis | 1 | 2025 | 16 | 0.220 |
Why?
| | Immunoglobulin Light Chains | 1 | 2025 | 52 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1969 | 0.210 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 165 | 0.210 |
Why?
| | Benzodioxoles | 1 | 2025 | 161 | 0.200 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2025 | 128 | 0.200 |
Why?
| | Seasons | 1 | 2026 | 538 | 0.200 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 206 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2025 | 883 | 0.200 |
Why?
| | MCF-7 Cells | 3 | 2020 | 133 | 0.200 |
Why?
| | Liver | 3 | 2024 | 1899 | 0.190 |
Why?
| | Quinolones | 1 | 2025 | 204 | 0.190 |
Why?
| | Nonsense Mediated mRNA Decay | 1 | 2023 | 20 | 0.190 |
Why?
| | Protein Isoforms | 2 | 2022 | 399 | 0.190 |
Why?
| | Aminophenols | 1 | 2025 | 203 | 0.190 |
Why?
| | Lipoproteins, LDL | 2 | 2020 | 119 | 0.190 |
Why?
| | RNA, Messenger | 5 | 2021 | 2805 | 0.190 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2023 | 29 | 0.190 |
Why?
| | Lymphatic Vessels | 2 | 2020 | 63 | 0.190 |
Why?
| | Estrogens | 4 | 2018 | 367 | 0.180 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2021 | 196 | 0.180 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 288 | 0.180 |
Why?
| | Calcium | 2 | 2025 | 1192 | 0.170 |
Why?
| | Fatty Liver | 1 | 2024 | 253 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 507 | 0.170 |
Why?
| | Azacitidine | 2 | 2022 | 157 | 0.170 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 62 | 0.170 |
Why?
| | Pyridines | 1 | 2025 | 609 | 0.170 |
Why?
| | Multiple Myeloma | 1 | 2025 | 309 | 0.170 |
Why?
| | Drosophila | 1 | 2022 | 166 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 2 | 2020 | 574 | 0.160 |
Why?
| | Cells, Cultured | 6 | 2019 | 4151 | 0.160 |
Why?
| | RNA, Small Cytoplasmic | 1 | 2020 | 7 | 0.160 |
Why?
| | Weight Gain | 2 | 2021 | 561 | 0.160 |
Why?
| | Neural Crest | 1 | 2021 | 129 | 0.150 |
Why?
| | rac GTP-Binding Proteins | 1 | 2020 | 35 | 0.150 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2020 | 36 | 0.150 |
Why?
| | Adipose Tissue | 2 | 2021 | 645 | 0.150 |
Why?
| | Gene Library | 2 | 2019 | 122 | 0.150 |
Why?
| | Receptors, Progesterone | 2 | 2020 | 244 | 0.150 |
Why?
| | DNA-Binding Proteins | 3 | 2020 | 1482 | 0.150 |
Why?
| | Extracellular Fluid | 1 | 2019 | 38 | 0.150 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 56 | 0.150 |
Why?
| | Gene Expression Profiling | 7 | 2024 | 1777 | 0.150 |
Why?
| | Integrins | 1 | 2020 | 90 | 0.150 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 72 | 0.150 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 200 | 0.140 |
Why?
| | Promoter Regions, Genetic | 3 | 2013 | 1247 | 0.140 |
Why?
| | Hematopoiesis | 1 | 2020 | 193 | 0.140 |
Why?
| | Neural Stem Cells | 1 | 2020 | 168 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 220 | 0.140 |
Why?
| | RNA Editing | 1 | 2018 | 26 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 273 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 981 | 0.140 |
Why?
| | Oligodendroglia | 1 | 2020 | 190 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 923 | 0.130 |
Why?
| | Motor Neurons | 1 | 2020 | 236 | 0.130 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 121 | 0.130 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 58 | 0.130 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2020 | 141 | 0.130 |
Why?
| | Bleomycin | 1 | 2019 | 255 | 0.130 |
Why?
| | Zebrafish Proteins | 1 | 2021 | 314 | 0.130 |
Why?
| | Superoxide Dismutase | 1 | 2019 | 308 | 0.130 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 153 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 688 | 0.130 |
Why?
| | RNA Polymerase III | 1 | 2017 | 34 | 0.130 |
Why?
| | Regeneration | 1 | 2019 | 198 | 0.130 |
Why?
| | Progestins | 1 | 2017 | 66 | 0.120 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3551 | 0.120 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 23 | 0.120 |
Why?
| | Macrophages, Alveolar | 1 | 2019 | 373 | 0.120 |
Why?
| | Obesity | 2 | 2021 | 3118 | 0.120 |
Why?
| | Zebrafish | 1 | 2021 | 532 | 0.120 |
Why?
| | Epididymis | 2 | 2013 | 14 | 0.120 |
Why?
| | Transforming Growth Factor beta | 1 | 2019 | 474 | 0.120 |
Why?
| | Apoptosis | 3 | 2019 | 2445 | 0.120 |
Why?
| | Bronchi | 1 | 2018 | 263 | 0.120 |
Why?
| | Epithelial Cells | 2 | 2013 | 1135 | 0.120 |
Why?
| | Trachea | 1 | 2018 | 258 | 0.120 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1329 | 0.120 |
Why?
| | Lung Injury | 1 | 2019 | 249 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2017 | 770 | 0.110 |
Why?
| | Temperature | 1 | 2018 | 633 | 0.110 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 93 | 0.110 |
Why?
| | DNA Primers | 1 | 2016 | 505 | 0.110 |
Why?
| | Extracellular Matrix | 1 | 2019 | 563 | 0.110 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 778 | 0.110 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 611 | 0.110 |
Why?
| | Hypoxia | 1 | 2022 | 1199 | 0.110 |
Why?
| | CCCTC-Binding Factor | 2 | 2011 | 12 | 0.100 |
Why?
| | Chromosome Mapping | 2 | 2013 | 507 | 0.100 |
Why?
| | Tamoxifen | 3 | 2021 | 193 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 979 | 0.100 |
Why?
| | Male | 12 | 2026 | 73012 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 910 | 0.100 |
Why?
| | Down-Regulation | 1 | 2015 | 618 | 0.100 |
Why?
| | Spermatogenesis | 1 | 2013 | 91 | 0.100 |
Why?
| | Nucleosomes | 2 | 2013 | 163 | 0.100 |
Why?
| | Infertility, Male | 1 | 2013 | 80 | 0.100 |
Why?
| | Cluster Analysis | 3 | 2022 | 501 | 0.100 |
Why?
| | Enhancer Elements, Genetic | 2 | 2012 | 191 | 0.100 |
Why?
| | Neoplasms | 2 | 2021 | 2913 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2024 | 5995 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2019 | 878 | 0.090 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2013 | 108 | 0.090 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 209 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 328 | 0.090 |
Why?
| | Genetic Vectors | 1 | 2013 | 335 | 0.090 |
Why?
| | Genes, Regulator | 1 | 2011 | 35 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 534 | 0.090 |
Why?
| | Caco-2 Cells | 1 | 2011 | 79 | 0.090 |
Why?
| | Luciferases | 1 | 2011 | 154 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 2000 | 0.080 |
Why?
| | Female | 13 | 2025 | 79045 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2021 | 2192 | 0.080 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2011 | 90 | 0.080 |
Why?
| | Oxidative Phosphorylation | 2 | 2024 | 209 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1957 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2240 | 0.080 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 735 | 0.080 |
Why?
| | Insulator Elements | 1 | 2009 | 1 | 0.070 |
Why?
| | 3' Flanking Region | 1 | 2009 | 7 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1184 | 0.070 |
Why?
| | CD146 Antigen | 2 | 2020 | 38 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2885 | 0.070 |
Why?
| | Prognosis | 3 | 2025 | 4330 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 887 | 0.060 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2024 | 4568 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2969 | 0.060 |
Why?
| | Airway Remodeling | 1 | 2025 | 63 | 0.060 |
Why?
| | Blast Crisis | 1 | 2025 | 34 | 0.050 |
Why?
| | Chloride Channel Agonists | 1 | 2025 | 110 | 0.050 |
Why?
| | Pyrrolidines | 1 | 2025 | 125 | 0.050 |
Why?
| | Chromatin | 1 | 2009 | 553 | 0.050 |
Why?
| | Quinolines | 1 | 2025 | 190 | 0.050 |
Why?
| | Drug Combinations | 1 | 2025 | 396 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 90 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2865 | 0.050 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2023 | 27 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2024 | 322 | 0.050 |
Why?
| | Bone Marrow | 1 | 2024 | 307 | 0.050 |
Why?
| | Cell Survival | 1 | 2025 | 1105 | 0.040 |
Why?
| | Mice, Obese | 1 | 2021 | 68 | 0.040 |
Why?
| | Pyrazoles | 1 | 2025 | 517 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 100 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 81 | 0.040 |
Why?
| | Phosphorylation | 1 | 2025 | 1708 | 0.040 |
Why?
| | Intercellular Junctions | 1 | 2020 | 35 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 673 | 0.040 |
Why?
| | Organogenesis | 1 | 2021 | 63 | 0.040 |
Why?
| | Proteostasis | 1 | 2020 | 27 | 0.040 |
Why?
| | Child | 1 | 2020 | 22740 | 0.040 |
Why?
| | Embryoid Bodies | 1 | 2020 | 8 | 0.040 |
Why?
| | Permeability | 1 | 2020 | 169 | 0.040 |
Why?
| | Morphogenesis | 1 | 2021 | 171 | 0.040 |
Why?
| | Colony-Forming Units Assay | 1 | 2020 | 95 | 0.040 |
Why?
| | Skull | 1 | 2021 | 163 | 0.040 |
Why?
| | Head | 1 | 2021 | 123 | 0.040 |
Why?
| | Cartilage | 1 | 2021 | 198 | 0.040 |
Why?
| | Exocytosis | 1 | 2019 | 85 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.040 |
Why?
| | Mesoderm | 1 | 2020 | 147 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 11794 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2020 | 266 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 22 | 0.040 |
Why?
| | Transcription Factors | 2 | 2021 | 1736 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 27 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 273 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 140 | 0.030 |
Why?
| | Cytokines | 1 | 2026 | 2069 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.030 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 65 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 45 | 0.030 |
Why?
| | Gene Editing | 1 | 2019 | 89 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2020 | 451 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 508 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 322 | 0.030 |
Why?
| | Lung | 2 | 2022 | 4116 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 241 | 0.030 |
Why?
| | Fatty Acids | 1 | 2020 | 457 | 0.030 |
Why?
| | Fibrosis | 1 | 2019 | 561 | 0.030 |
Why?
| | Amino Acids | 1 | 2020 | 519 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 635 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 587 | 0.030 |
Why?
| | Mice, SCID | 1 | 2017 | 369 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8347 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 336 | 0.030 |
Why?
| | Stem Cells | 1 | 2020 | 630 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2017 | 616 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 67 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 858 | 0.030 |
Why?
| | Aged | 3 | 2020 | 26217 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2018 | 494 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 1028 | 0.030 |
Why?
| | Macrophages | 1 | 2022 | 1507 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 42 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 936 | 0.030 |
Why?
| | Expert Systems | 1 | 2013 | 4 | 0.030 |
Why?
| | DNA, Intergenic | 1 | 2013 | 26 | 0.020 |
Why?
| | Adult | 3 | 2025 | 40882 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2014 | 311 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2219 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1812 | 0.020 |
Why?
| | Organ Specificity | 1 | 2013 | 309 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2018 | 935 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 475 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3130 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2181 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 751 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 244 | 0.020 |
Why?
| | Diet | 1 | 2018 | 1278 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5585 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2514 | 0.020 |
Why?
| | DNA Footprinting | 1 | 2009 | 33 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 804 | 0.020 |
Why?
| | Deoxyribonuclease I | 1 | 2009 | 41 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 669 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 14254 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4302 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2171 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1430 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2933 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 36309 | 0.010 |
Why?
|
|
Gillen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|